相关实验视频

Updated: Jan 16, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

帕埃诺尔通过抑制增殖和NF-κB-在和实验研究改善良性前列腺增生症

Han-Young Lee¹, Min-Seong Lee¹, Byung-Cheol Lee¹

¹Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.

Pharmaceuticals (Basel, Switzerland)

|September 27, 2025

概括

帕埃诺尔通过抑制5α-减小酶2 (5AR2) 和雄激素受体 (AR) 等关键点,通过网络药理学和体内研究有效治疗良性前列腺增生 (BPH),减少前列腺生长和炎症.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
药理学药理学是指药理学的学科.
计算生物学计算生物学

背景情况:

良性前列腺增生 (BPH) 是老年男性常见的疾病,导致下泌尿道症状.
来自Moutan Cortex的Paeonol已知药理性质,但其在BPH治疗中的作用尚未被探索.
了解BPH中醇的机制对于开发新疗法至关重要.

研究的目的:

调查帕埃诺尔在治疗良性前列腺增生症 (BPH) 的治疗机制.
通过使用网络药理学和分子对接,识别与BPH相关的paeonol的潜在分子标.
为了验证paeonol在丸激素诱导的BPH大鼠模型中的疗效.

主要方法:

网络药理学和分子对接被用来预测BPH中paeonol的点.
在体内实验中建立了由激素诱导的BPH的老鼠模型.
分析了前列腺的体重,体积,组织学和基因表达 (qRT-PCR),以评估帕埃诺的作用.

主要成果:

在分析中,确定了与亡,增殖,PI3K-Akt信号传递和炎症相关的途径.
在BPH大鼠中,Paeonol治疗显著降低了前列腺体重,体积和前列腺增生.
醇抑制了5α-减少酶2 (5AR2) 和雄激素受体 (AR),并降低了Akt1,NF-κB和GR的表达.

结论:

帕埃诺尔证明了BPH的多目标治疗潜力.
它通过抑制5AR2和AR而起作用,这对于BPH中雄激素信号传递至关重要.
帕埃诺尔通过调节NF-κB和Akt通路来抑制BPH增殖和炎症.

关键词:

这就是为什么Akt1 Akt1 Akt1 Akt1 Akt1 这就是NF-κBB.良性前列腺增生症良性前列腺增生症二二二二二二二二二二二二二二在Paeonol中使用Paeonol.它们的扩散和扩散.

更多相关视频

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...